Mogamulizumab as Bridge to Thiotepa‐Based Allogeneic Haematopoietic Stem Cell Transplantation in Sézary Syndrome: A Single‐Centre Experience

Simone Maifredi, Raffaella Sala, Chiara Bottelli, Chiara Pagani, Angela Passi, Rosa Daffini, Alessia Pantaleo, Domenico Russo, Michele Malagola, Marina Venturini, Daniele Avenoso, Alessandra Tucci · 2026

Read Mogamulizumab as Bridge to Thiotepa‐Based Allogeneic Haematopoietic Stem Cell Transplantation in Sézary Syndrome: A Single‐Centre Experience by Simone Maifredi, Raffaella Sala, Chiara Bottelli, Chiara Pagani, Angela Passi, Rosa Daffini, Alessia Pantaleo, Domenico Russo, Michele Malagola, Marina Venturini, Daniele Avenoso, Alessandra Tucci (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13270391.txt.

Description

Simone Maifredi and co-authors published a case series in 2026 on three patients with Sézary syndrome, an aggressive skin T-cell lymphoma, treated at one center. A stem cell transplant from a donor is the only potentially curative option. The antibody drug mogamulizumab was used first to control disease before transplant.

The drug rapidly cleared circulating cancer cells and brought significant clinical improvement in all three patients. All then received transplants with a thiotepa-based gentler preparation. Each patient achieved early, stable full donor cell takeover and complete remission. Graft-versus-host disease, where donor cells attack the body, occurred after transplant but was manageable with standard therapy. The authors support early use of the drug as a bridge.

Catalog record

CREATORSimone Maifredi, Raffaella Sala, Chiara Bottelli, Chiara Pagani, Angela Passi, Rosa Daffini, Alessia Pantaleo, Domenico Russo, Michele Malagola, Marina Venturini, Daniele Avenoso, Alessandra Tucci
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE12603
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13270391

Browse the full library · About the Tower of Babel